Genentech has initiated an expansion cohort in Phase I trial of a Hedgehog antagonist, triggering a $3 million cash payment to Curis, Inc. under the companies’ June 2003 collaboration agreement. The Phase I trial expansion satisfies the criteria for a Phase II trial. Genentech began the open-label Phase I trial in January 2007 to study a systemic Hedgehog antagonist in patients with locally advanced or metastatic cancers that have not responded to standard therapy or for whom no stand...